Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Paricalcitol (Zemplar®) capsules are not recommended for use within NHS Wales for the treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease (CKD) Stages 3 and 4) patients and chronic renal failure (CKD Stage 5) patients on haemodialysis or peritoneal dialysis. Insufficient evidence of clinical and cost effectiveness was presented for AWMSG to recommend its use within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | paricalcitol (Zemplar®) | |
| Formulation | 1 microgram, 2 micrograms and 3 micrograms capsules and 5 micrograms/ml solution for injection | |
| Reference number | 238 | |
| Indication | Prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease Stages 3 and 4) patients and chronic renal failure (chronic kidney disease Stage 5) patients on haemodialysis or peritoneal dialysis |
|
| Company | AbbVie Ltd | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Full | |
| Status | Not recommended | |
| Advice number | 1309 | |
| NMG meeting date | 15/07/2009 | |
| AWMSG meeting date | 12/08/2009 | |
| Ratification by Welsh Government | 11/09/2009 | |
| Date of issue | 15/09/2009 | |